AI Article Synopsis
- The text reviews fezolinetant as a treatment for menopause-related vasomotor symptoms, highlighting its mechanism of action by inhibiting neurokinin B from binding to receptors in the hypothalamus.
- Clinical trials indicate that fezolinetant is more effective than a placebo at reducing both the frequency and severity of these symptoms, though it does have common side effects like headaches and gastrointestinal issues.
- With fezolinetant approved and elinzanetant in phase 3 trials, patients now have nonhormonal alternatives to hormone therapy, which may not be suitable for everyone due to associated risks.
Article Abstract
To review the safety, efficacy, and tolerability of fezolinetant for the treatment of vasomotor symptoms associated with menopause. A literature search was conducted through PubMed using the following search terms: fezolinetant, ES259564, SKYLIGHT, vasomotor symptoms, and menopause. Selected articles included those which described clinical studies of the pharmacology, pharmacokinetics, efficacy, safety, or tolerability of fezolinetant. Fezolinetant works by inhibiting neurokinin B from binding to its receptor in the hypothalamus, thereby decreasing the occurrence of vasomotor symptoms. Clinical trials have demonstrated fezolinetant is superior to placebo in decreasing the frequency and severity of vasomotor symptoms. Common adverse effects associated with the use of fezolinetant include headache and gastrointestinal disturbances, as well as elevations in liver transaminase levels. Clinical practice guidelines for the treatment of vasomotor symptoms associated with menopause recommend hormone therapy as the most effective treatment option. Risks associated with hormone use may limit the use of this option in some patients. Neurokinin B inhibitors, like fezolinetant, target the physiologic cause of vasomotor symptoms. With the approval of fezolinetant, as well as elinzanetant which is currently in phase 3 clinical trials, providers and patients have additional nonhormonal treatment options for vasomotor symptoms associated with menopause.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640863 | PMC |
| http://dx.doi.org/10.1177/87551225231198700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: To analyze the dynamics of the condition of the mucous membrane in patients with metabolic syndrome at the stage of preparation for dental prosthetics using dental implants.
Material And Methods: 255 patients (151 women and 104 men) aged from 35 to 65 years were examined. 3 groups were formed: 2 study groups and a comparison group.
Arteriolar Elasticity Measurement in the Fingertip Based on Photoplethysmographic Volume-Oscillometry: A New Approach to the Assessment of Vasomotor Functions in the Microvasculature.
Cardiovasc Eng Technol
January 2025
Department of Research and Development, Nonprofit Organization of Research Institute of Life Benefit, Sapporo, Hokkaido, 005-0006, Japan.
Purpose: Dysfunction of vasomotor reactions due to arteriolar smooth muscle causes serious adverse events, such as loss of hemodynamic coherence. This in turn can increase risks of cardiovascular-related diseases. A noninvasive and quantitative evaluation of microvascular disorder is therefore very important for early diagnosis and treatment.
View Article and Find Full Text PDFThe case of a woman with bilateral Dupuytren's contractures who developed CRPS-1 after fasciectomy with no relapse on subsequent collagenase clostridium histolyticum injection and manipulation of the other hand: Considerations for implementing a Budapest criteria checklist and assessing vasomotor instability by measuring differences in skin temperature.
J Hand Ther
January 2025
Saint Joseph, MI, USA. Electronic address:
Background: For patients who experience atypical neurogenic pain thought to be complex regional pain syndrome (CRPS) after Dupuytren's fasciectomy early recognition has been reported to improve outcomes. Furthermore, given the progressive nature of Dupuytren's, individuals with a history of CRPS have been "at risk" for further surgical intervention.
Purpose: To familiarize therapists with a Budapest criteria (BC) checklist for early diagnosis of CRPS, describe how tracking sudomotor/vasomotor signs alongside differences in skin temperature were used to monitor vasomotor instability and intervention effectiveness for a patient with atypical pain after fasciectomy and to detail management of the same patient with a CRPS history who had collagenase clostridium histolyticum (CCH) injection of her other hand without exacerbating CRPS.
Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Arch Gynecol Obstet
January 2025
Gynecology Department, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, S/N, 28040, Madrid, Spain.
Purpose: Uterine fibroids are the most common pelvic tumors in women, representing the primary indication of hysterectomy. Gonadotropin-releasing hormone (GnRH) antagonists represent a new therapeutic option for premenopausal women. The aim of this review is to evaluate the efficacy and safety of GnRH antagonists in the treatment of uterine fibroids (size reduction and symptom control).
View Article and Find Full Text PDFUpdates in nonhormonal therapy for perimenopausal and menopausal symptoms.
Curr Opin Obstet Gynecol
January 2025
Division of Complex Family Planning, Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford, California, USA.
Purpose Of Review: Perimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!